Roche touts PhII win for BTK inhibitor in multiple sclerosis as PhIII showdown with Sanofi, Merck KGaA, Novartis looms
Roche is staking its claim in the race to develop a BTK inhibitor for multiple sclerosis, with a topline Phase II win showing its candidate reduced brain lesions.
There are no numbers yet — Roche and its subsidiary Genentech are saving those for a medical meeting — but the companies suggested that the positive result bodes well for the Phase III trials they are running for in relapsing MS and primary progressive MS.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.